The European Medicines Agency has recommended pan-EU marketing approval for eight new medicines including Evkeeza (evinacumab), Regeneron Pharmaceuticals’ treatment for homozygous familial hypercholesterolemia (HoFH), a genetic condition that causes severely high cholesterol levels.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?